Brief: Veru Announces Full Enrollment For Phase 2B Plateau Clinical Trial Of Enobosarm And Semaglutide Combination For High Quality Weight Loss
27/07/2026 13:27
BRIEF-Veru Announces Full Enrollment For Phase 2B Plateau Clinical Trial Of Enobosarm And Semaglutide Combination For High Quality Weight Loss July 27 (Reuters) - Veru Inc VERU.O:
VERU ANNOUNCES FULL ENROLLMENT FOR PHASE 2B PLATEAU CLINICAL TRIAL OF ENOBOSARM AND SEMAGLUTIDE COMBINATION FOR HIGH QUALITY WEIGHT LOSS
VERU - INTERIM ANALYSIS RESULTS FOR PHASE 2B PLATEAU TRIAL EXPECTED IN Q1 2027
VERU - FINAL TOPLINE DATA FOR PHASE 2B PLATEAU TRIAL EXPECTED IN Q4 2027
Source text: ID:nGNX4ptqBQ
Further company coverage: VERU.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Veru
See all newsUS STOCKS ON THE MOVE-Netflix, Coinbase Global, Accenture
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal
Oppenheimer upbeat on Veru, says 'come for the lean mass, stay for the muscle function'
Veru Inc. reports results for the quarter ended June 30 - Earnings Summary